Benzinga · Oct 28, 2026
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.
CG
NASDAQ · CGEM
Cullinan Therapeutics, Inc.
Healthcare · Medical - Pharmaceuticals
$15.75
Down-$1.84 (-11.65%)
Updated Nov 4, 2026, 4:36 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 730.18M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $6.73 – $23.19
- Volume
- 789.74K
- Avg. volume
- 1.2M
Price performance · CGEM
CGEM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
CGEM closed at $15.75 after 21 trading sessions, down 3.08% for the selected period.
- Last close
- $15.75
- Period change
- -3.08%
- Period low
- $12.93
- Period high
- $16.25
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $15.04 | $16.20 | $14.975 | $15.75 | 789.74K |
| Nov 2, 2026 | $15.13 | $15.345 | $14.63 | $14.93 | 730.77K |
| Oct 30, 2026 | $15.38 | $15.72 | $14.7001 | $15.03 | 389.41K |
| Oct 29, 2026 | $15.60 | $16.185 | $15.35 | $15.45 | 460.06K |
| Oct 28, 2026 | $14.93 | $15.6163 | $14.72 | $15.56 | 594.32K |
| Oct 27, 2026 | $14.66 | $14.98 | $14.28 | $14.84 | 488.23K |
| Oct 26, 2026 | $14.71 | $14.87 | $14.39 | $14.54 | 438.58K |
| Oct 23, 2026 | $14.945 | $14.945 | $13.86 | $14.37 | 485.2K |
| Oct 22, 2026 | $14.82 | $15.32 | $14.64 | $14.92 | 392.65K |
| Oct 21, 2026 | $14.92 | $15.26 | $14.64 | $14.89 | 690.98K |
| Oct 20, 2026 | $13.92 | $14.92 | $13.85 | $14.83 | 694.02K |
| Oct 19, 2026 | $13.02 | $14.00 | $12.77 | $13.98 | 862.46K |
| Oct 16, 2026 | $13.91 | $13.91 | $12.81 | $12.93 | 1.12M |
| Oct 15, 2026 | $13.62 | $14.18 | $13.455 | $14.00 | 972.11K |
| Oct 14, 2026 | $13.81 | $14.18 | $13.44 | $13.64 | 903.55K |
| Oct 13, 2026 | $14.86 | $14.93 | $14.075 | $14.10 | 590.35K |
| Oct 12, 2026 | $15.45 | $15.64 | $14.88 | $14.95 | 372.44K |
| Oct 9, 2026 | $15.41 | $15.95 | $15.235 | $15.53 | 567.53K |
| Oct 8, 2026 | $15.60 | $15.71 | $14.81 | $15.46 | 1.14M |
| Oct 7, 2026 | $15.95 | $16.46 | $15.472 | $15.63 | 808.19K |
| Oct 6, 2026 | $17.24 | $17.70 | $16.06 | $16.25 | 2.02M |
Latest CGEM news
The latest Smart Investors Daily articles mentioning CGEM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CGEM research
Overview
Company profile and research snapshot.
Company profile
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $32.67
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | BTIG | Buy | — |
| Oct 19, 2026 | BTIG | Buy | — |
| Oct 2, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 25, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 25, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias, evaluating a short-duration subcutaneous regimen designed to deplete antibody-producing plasma cells CAMBRIDGE, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-mo
Benzinga · Oct 27, 2026
Cullinan Therapeutics Gets FDA And Australian Therapeutic Goods Administration Clearance To Initiate Its Global Phase 1b/2a Clinical Trial In Adults With Relapsing And Refractory ITP And Warm Autoimmune Hemolytic Anemia
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHAStudy expands immunology portfolio into autoimmune cytopenias, evaluating a
Benzinga · Oct 19, 2026
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
